Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. moved from very attractive to attractive, indicating a shift in perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 20, a Price to Book Value of 2.48, and an EV to EBITDA of 14.39. In comparison, peers such as Alkermes Plc have a P/E of 13.77 and an EV to EBITDA of 9.41, suggesting that Prestige is trading at a premium relative to its industry.
The stock has underperformed against the S&P 500 over various periods, notably with a year-to-date return of -20.49% compared to the index's 13.30%. This underperformance, alongside the elevated valuation ratios, reinforces the conclusion that Prestige Consumer Healthcare, Inc. is currently overvalued.